Publications on COVID-19 and CML/Cancer - 2021

December 2021

• Durable humoral responses after the second anti-SARS-CoV-2 vaccine dose in chronic leukemia patients on tyrosine kinase inhibitors
  Claudiani S et al. Br J Haematol, December 2021 (epub ahead of print) – open access publication
• Safety of SARS-CoV-2 vaccines in patients with chronic myeloid leukemia: a multicentre survey in China
  Yang et al. Clin Med J (Engl), December 2021 (epub ahead of print) – open access publication
• Outcome of COVID-19 in patients with CML: A single centre UK experience
  Nesr G et al. J Med Virol, December 2021 (epub ahead of print)
• Serum antibody response in patients with Philadelphia-chromosome positive or negative myeloproliferative neoplasms following vaccination with SARS-CoV-2 spike protein messenger RNA (mRNA) vaccines
  Kozak KE et al. Leukemia, December 2021 – open access publication
• Evaluation of COVID-10 vaccine response in patients with cancer: An interim analysis
  Tran S et al. Eur J Cancer, December 2021 – open access publication
• Immune response following third COVID-19 vaccination are reduced in patients with haematological malignancies compared to patients with solid cancer
  Fendler A et al. Cancer Cell, December 2021 (epub ahead of print) – open access publication
• Immune biomarkers to predict SARS-CoV-2 vaccine effectiveness in patients with haematological malignancies
  Tamariz-Amador LE. Blood Cancer J, December 2021 – open access publication
• Low rate of seroconversion after mRNA anti-SARS-CoV-2 vaccination in patients with haematological malignancies
  Re D et al. Leuk Lymphoma, December 2021
• Systematic screening for SARS-CoV-2 in patients with haematological malignancies on active anticancer treatment in the outpatient setting
  Varettoni M et al. Leuk Lymphoma, December 2021
• Efficacy and safety of heterologous booster vaccination with Ad26Cov2.S after BNT162b2 mRNA COVID-19 vaccine in haemato-oncological patients with no antibody response
  Reimann P et al. Br J Haematol, December 2021 (epub ahead of print) – open access publication
• Antibody response after vaccination against SARS-CoV-2 in adults with haematological malignancies: a systematic review and meta-analysis
  Gagelmann N et al. Haematologica, December 2021 (epub ahead of print) – open access publication

November 2021

• Is COVID-19 less severe in CML patients than in those with other haematological cancers?
  Claudiani S. Br J Haematol, October 2021 (epub ahead of print) – open access publication
• Serological SARS-CoV-2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID-19 vaccine in haematological and oncological patients
  Benda M et al. B J Haematol, November 2021 – open access publication
• COVID-19 in vaccinated adult patients with haematological malignancies: preliminary results from EPICOVIDEHA
  Pagano L et al. Blood, November 2021 (epub ahead of print)

October 2021

• COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A campus CML report
  Breccia M et al. Br J Haematol, October 2021 (epub ahead of print) - open access publication
  
• COVID-19 infection in adult patient with haematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)
  Pagano L et al. J Hematol Oncol, October 2021 – open access publication
• Elevated acute phase proteins affect pharmacokinetics in COVID-19 trials. Lessons from the CounterCOVID-imatinib study
  Bartelink IH et al. CPT Pharmacometics Syst Pharmacol, October 2021
  (epub ahead of print) – open access publication
• COVID-19 and seasonal influenza: a comparative analysis in patients with haematological malignancies
  Modemann F et al. Leuk Lymphoma, October 2021 (epub ahead of print)
• BNT162b2 COVID-19 vaccine is significantly less effective in patients with haematological malignancies
  Herzog-Tzarfati K et al. Am J Hematol, October 2021 – open access publication
• COVID-19 in pediatric cancer patients is associated with treatment interruptions but not with short-term mortality: a Polish National study
  Weclawek-Tampol J et al. J Hematol Oncol, October 2021 – open access publication

September 2021

• The serological prevalence of SARS-CoV-2 infection in patients with chronic myeloid leukemia is similar to that in the general population
  Bonifacio M et al. Cancer Med, September 2021 – open access publication
• Clinical profile and outcomes of COVID-19 in haematological malignancies: experience from tertiary care centre in India
  Gupta A et al. Ann Hematol, September 2021 (epub ahead of print)
• Clinical characteristics and outcomes of patients with haematological malignancies and COVI-19 suggest that prolonged SARS-CoV-2 carriage is an important issue
  Arcani R et al. Ann Hematol, September 2021 (epub ahead of print) – open access publication
• Implementation of a hospital-at-home (HAH) unit for haematological patients during the COVID-19 pandemic: safety and feasibility
  Gómez-Centurión I et al. Int J Hematol, September 2021 (epub ahead of print) – open access publication

August 2021

• The care of the leukemic patients in times of SARS-CoV-2
  Karki NK et al. Curr Oncol Rep, August 2021 – open access publication
• A novel system for semiautomatic sample processing in chronic myeloid leukemia: Increasing throughput without impacting on molecular monitoring at time of SARS-CoV-2 pandemic
  Stella S et al. Diagnostics (Basel), August 2021 – open access publication
• COVID-19 among patients with haematological malignancies: A national Israeli retrospective analysis with special emphasis on treatment and outcome
  Levy I et al. Leuk Lymphoma, August 2021 (epub ahead of print)
• Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies
  Malard F et al. Blood Cancer J, August 2021 – open access publication
• Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies
  Greenberger LM et al. Cancer Cell, August 2021 – open access publication
• Multiple cranial nerve palsies revealing blast crisis in patient with chronic myeloid leukemia in the accelerated phase under nilotinib during severe infection with SARS-CoV-19 virus: Case report and review of literature
  Bouchlarhem A et al. Radiol Case Rep, August 2021 (epub ahead of print) – open access publication
• Global characteristics and outcomes of SARS-CoV-2 infection in children and adolescents with cancer (GRCCC): a cohort study
  Mukkada S et al. Lancet Oncol, August 2021 (epub ahead of print)
  
• Seroconversion and kinetic of anti SARS-CoV-2 antibodies in 25 patients with haematological malignancies who recovered from SARS-CoV-2 infection
  Candoni A et al. Hematol Oncol, August 2021 – open access publication

July 2021

• COVID-19 in chronic myeloid leukemia patients in Latin America
  Pagnano KB et al. Leuk Lymphoma, July 2021 (epub ahead of print)
• Preclinical evaluation of imatinib does not support its use as an antiviral drug against SARS-CoV-2
  Touret F et al. Antiviral Res, July 2021 (epub ahead of print) – open access publication
• COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies
  Passamonti F et al. Br J Haematol, July 2021 (epub ahead of print) – open access publication
  

June 2021

• Single dose BNT162b1 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with CML
  Harrington P et al. Br J Haematol, June 2021 (epub ahead of print)
  – open access publication
• Mental health in persons with chronic myeloid leukemia during the SARS-CoV-2 pandemic: The need for increased access to healthcare services
  Bao M et al. Front Psychiatry, June 2021 – open access publication
• The impact of COVID-19 on patients with haematological malignancies: the mixed-method analysis of an Israeli National survey
  Levy I et al. Support Care Cancer, June 2021 (epub ahead of print) – open access publication
• COVID-19 and stem cell transplantation; results from an EBMT and GETH multicentre prospective survey
  Ljungman P et al. Leukemia, June 2021 (epub ahead of print) – open access publication
• Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and cancer Consortium
  Grivas P et al. Ann Oncol, June 2021 – open access publication
• Epidemiological and clinical characteristics of cancer patients with COVID-19: A systematic review and meta-analysis of global data
  Kong X et al. Cancer Lett, June 2021 – open access publication
  
  

May 2021

• Impact of COVID-19 on cancer care in India: A cohort study
  Ranganathan P et al. Lancet Oncol, May 2021 (epub ahead of print) - open access publication
• When hematologic malignancies meet COVID-19 in the United State: Infections, death and disparities
  Wang Q et al. Blood Rev, May 2021
• COVID-19 among children with cancer in Greece (2020). Results from the Nationwide Registry of Childhood Hematological Malignancies and Solid Tumours (NARECHEM-ST)
  Baka M et al. Pediatr Blood Cancer, May 2021 (epub ahead of print) - open access publication
• COVID-19 vaccines for patients with haematological conditions
  Sun C et al. Lancet Hematol, May 2021 – open access publication
• Mortality in hospitalized patients with cancer and coronavirus disease 2019: A systematic review and meta-analysis of cohort studies
  Desai A et al. Cancer, May 2021 – open access publication
• Comparison and impact of COVID-19 for patients with cancer: a survival analysis of fatality rate for age, sex and cancer type
  Li H et al. BMJ Health Care Inform, May 2021 – open access publication

April 2021

• Clinical characteristics and risk factors for mortality in cancer patients with COVID-19
  Liang J et al. Front Med, April 2021 – open access publication
• 2021 update of the AGIHO Guideline on evidence-based management of COVID-19 in patients with cancer regarding diagnosis, viral shredding, vaccination and therapy
  Giesen N et al. Eur J Cancer, April 2021 – open access publication
• Consequences of the COVID-19 pandemic on cancer clinical trials
  Flores S et al. Cancer Med J, April 2021 – open access publication
• Impact of cancer history on outcomes among hospitalized COVID-19 patients
  Klein IA et al. Oncologist, April 2021 – open access publication
• COVID-19 and cancer – 1 year on
  The Lancet Oncology, April 2021 – open access publication

March 2021

• Early administration of convalescent plasma improves survival in patients with haematological malignancies and COVID-19
  Biernat MM et al. Viruses, March 2021 – open access publication
• Risk stratification and outreach to hematology/oncology patients during the COVID-19 pandemic
  Osterman CK et al. Support Care Cancer, March 2021 – open access publication
• COVID-19 in chronic-phase chronic myeloid leukemia patients: A single-center survey from Turkey
  Yilmaz U et al. Turk J Haematol, February 2021 – open access publication
• Blurring of vision as the only symptom of undiagnosed case of chronic myeloid leukemia in the COVID-19 era
  Gumaste P and Vairagyam R. Indian J Ophthalmol, March 2021 – open access publication
• Mild clinical course of COVID-19 infection in chronic myeloid leukemia (CML) patients receiving tyrosine kinase inhibitors (TKI’s) without interruption
  Demeter J et al. Mediterr J Hematol Infect Dis, March 2021 – open access publication
• COVID-19 in patients with haematological malignancies: Considering the role of tyrosine kinase inhibitors
  Morale-Ortega A et al. Cancer, March 2021 (epub ahead of print) – open access publication
  
• Reply to COVID-19 in patients with haematological malignancies: Considering the role of tyrosine kinase inhibitors
  Cattaneo C et al. Cancer, March 2021 (epub ahead of print) – open access publication
  
• Clinical presentations and outcomes of children with cancer and COVID-19: A systematic review
  Prasad Meena J et al. Pediatr Blood Cancer, March 2021 (epub ahead of print) – open access publication
• Challenges and opportunities for COVID-19 vaccines in patients with cancer
  Kuderer NM et al. Cancer Invest, March 2021
  
  

February 2021

• Kinase inhibitors developed for treatment of hematologic malignancies: implications for immune modulation in COVID-19
  Jacobs CF et al. Blood Adv, February 2021 - open access publication
• ASH registry offers insights on COVID-19 in patients with haematological malignancies
  Oncologist, February 2021 – open access publication
• Reduction in the rate and improvement in the prognosis of COVID-19 in haematological patients over time
  Cattaneo C et al. Leukemia, February 2021 – open access publication
• Priority COVID-19 vaccination for patients with cancer while vaccine supply is limited
  Ribas A et al. Cancer Discov, February 2021
• Cancer patients and COVID-19: Mortality, serious complications, biomarkers, and ways forward
  Gupta K et al. Cancer Treat Res Commun 2021 - open access publication

January 2021

• COVID-19 induced Pancytopenia in a major molecular response CML patient on dasatinib: A case report and review of the literature
  Singh B et al. Eur J Case Rep Intern Med, January 2021 – open access publication
  
• Lymphopenia as a biological predictor of outcomes in COVID-19 patients: A Nationwide Cohort Study
  Lee J et al. Cancers(Basel), January 2021 – open access publication